Skip to Content

'
Richard De La Garza II, Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Psychiatry & Behavioral Sciences, Menninger Clinic of Baylor College of Medicine, Houston, TX
Associate Professor, Department of Psychiatry, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Associate Professor, Pharmacology, University of Texas Medical Branch, Houston, TX
Associate Professor, rch Services Line, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX
Associate Professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Pharmacology, Baylor College of Medicine, Houston, TX
Associate Professor, Neuroscience, Baylor College of Medicine, Houston, TX

Education & Training

Degree-Granting Education

1996 University of North Texas, Denton, TX, MS, Neuroscience
1996 UT Medical Branch, Galveston, TX, PHD, Neuroscience
1985 Texas A&M University - East Texas, Commerce, TX, BS, Biology

Postgraduate Training

1999-2000 Research Fellowship, Neuroscience, Yale University School of Medicine, New Haven, CT
1996-1999 Research Fellowship, Neuroscience, Harvard Medical School, Boston, MA

Experience/Service

Academic Appointments

Visiting Associate Professor, Psychiatry & Behavioral Science, David Geffen School of Medicine at UCLA, Los Angeles, CA, 2007-2008
Associate Research Neuroscientist & Lecturer, Psychiatry & Behavioral Science, David Geffen School of Medicine at UCLA, Los Angeles, CA, 2004-2007
Assistant Professor, Psychiatry & Behavioral Science, Albert Einstein College of Medicine, New York, NY, 2000-2004
Associate Research Scientist, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, 1999-2000

Professional Memberships

Society for Neuroscience
Member, 1991-present
Society for Research on Nicotine and Tobacco
Member, 2008-present
Society on Stimulus Properties on Drugs
Member, 1994-1999

Selected Publications

Peer-Reviewed Original Research Articles
1. De La Garza R, Zorick T, London ED, Newton TF. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend 106(2-3):173-80, 1/2010. e-Pub 9/2009. PMCID: PMC2815156.
2. De La Garza R, Ashbrook LH, Evans SE, Jacobsen CA, Kalechstein AD, Newton TF. Influence of verbal recall of a recent stress experience on anxiety and desire for cocaine in non-treatment seeking, cocaine-addicted volunteers. Am J Addict 18(18):481-87, Nov-Dec, 11/2009. PMID: 19874169.
3. De La Garza R, Zorick T, Heinzerling KG, Nusinowitz S, London ED, Shoptaw S, Moody DE, Newton TF. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. Pharmacol Biochem Behav 94(1):186-93, 11/2009. e-Pub 8/2009. PMCID: PMC2775447.
4. Newton TF, De La Garza R, Kalechstein AD, Tziortzis D, Jacobsen CA. Theories of addiction: methamphetamine users' explanations for continuing drug use and relapse. Am J Addict 18(18):294-300, Jul-Aug, 7/2009. PMID: 19444733.
5. Newton TF, Reid MS, De La Garza II R, Mahoney III JJ, Abad A, Condos R, Palamar J, Halkitis PN, Mojisak J, Anderson A, Li S-H, Elkashef A. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Intl J Neuropsychopharmacol(11):1037-45, 2009.
6. De La Garza II R, Shoptaw S, Newton TF. Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. Neuropsychopharmacol(12):677-85, 2009.
7. Culbertson C, Costello M, De La Garza II R, Newton TF. Unrestricted access to methamphetamine or cocaine in the past is associated with increased current use. Intl J Neuropsychopharmacol(11):729-41, 2009.
8. De La Garza II R, Mahoney III JJ, Culbertson C, Shoptaw S, Newton TF. The Acetylcholinesterase Inhibitor Rivastigmine Does Not Alter Total Choices for Methamphetamine, but May Reduce Positive Subjective Effects, in a Laboratory Model of Intravenous Self-Administration in Human Volunteers. Pharmacol Biochem Behavior(89):200-208, 2008.

Grant & Contract Support

Title: Stimulant Pharmacotherapy: Noradrenergic Targets
Funding Source: National Institute on Drug Abuse
Role: Co-Principal Investigator
Duration: 2009 - 2014
 
Title: Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
Funding Source: NIH/NIDA
Role: Principal Investigator
Duration: 2009 - 2013
 
Title: RTI-336 as a Treatment for Methamphetamine Dependence
Funding Source: National Institute on Drug Abuse
Role: Principal Investigator
Duration: 2009 - 2012
 
Title: Modafinil and Escitalopram for Cocain Dependence
Funding Source: NIH/NIDA
Role: Principal Investigator
Duration: 2009 - 2011
 
Title: Rivastigmine as a Treatment for Methamphetamine Dependence
Funding Source: NIH/NIDA
Role: Principal Investigator
Duration: 2008 - 2011
 
Title: D-cycloserine in Extinction Learning
Funding Source: NIH/NIDA
Role: Principal Investigator
Duration: 2008 - 2010
 
Title: Cycloserine Enhancement of Extinction Learning
Funding Source: National Institute on Drug Abuse
Role: Principal Investigator
Duration: 2007 - 2010

Last updated: 2/13/2012